Skip to content

CytomX Therapeutics CTMX Cash Flow Statement

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$18.25M-178%-$26.51M-240%-$14.23M-348%-$154K+97.6%$23.53M+70.6%
$4.71M+134%$1.48M-21.5%$1.38M-30.6%$1.43M-24.0%$2.01M+5.3%
-$25.55M-21.4%-$23.24M-16.8%-$15.55M+25.0%-$15.75M+19.4%-$21.04M+19.2%
$0-100%$201K+151%$27K-71.9%$119K+3.5%
-$192.78M-730%-$14.42M-195%$0-100%-$76.36M-455%$30.6M-31.8%
$234.49M$16.64M+640%$253K$93.55M+1,735%$0-100%
$16.16M+69.2%-$21.02M-$14.86M$1.44M-79.7%$9.55M-49.8%
-$25.55M-20.7%-$23.44M-17.3%-$15.42M+25.7%-$15.78M+19.7%-$21.16M+19.1%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does CytomX Therapeutics generate?
CytomX Therapeutics (CTMX) generated -$80.1M in operating cash flow over the trailing twelve months.
What is CytomX Therapeutics's free cash flow?
After $347.0K of capital expenditures, CytomX Therapeutics's free cash flow was -$80.2M over the trailing twelve months, up 1.7% year over year.
Where does CytomX Therapeutics's cash flow data come from?
Every line is extracted from CytomX Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.